Neonc Technologies Holdings Inc (NTHI)

Currency in USD
4.6800
+0.1200(+2.63%)
Real-time Data·
NTHI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.39004.8899
52 wk Range
3.005012.9900
Key Statistics
Prev. Close
4.56
Open
4.61
Day's Range
4.39-4.8899
52 wk Range
3.005-12.99
Volume
114.58K
Average Vol. (3m)
142.66K
1-Year Change
-20.1906%
Book Value / Share
-0.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NTHI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.0000
Upside
+241.88%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.0000
(+241.88% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Alliance Global Partners
Buy13.00+177.19%-New CoverageMay 19, 2026
Maxim Group
Buy20.00+326.44%-New CoverageMay 18, 2026
BTIG
Buy15.00+219.83%-New CoverageApr 24, 2026

Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
-0.58 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NTHI Income Statement

Compare NTHI to Peers and Sector

Metrics to compare
NTHI
Peers
Sector
Relationship
P/E Ratio
−2.4x−2.8x−0.3x
PEG Ratio
−0.320.000.00
Price / Book
−5.3x−3.5x2.6x
Price / LTM Sales
2,849.9x2.6x3.1x
Upside (Analyst Target)
225.4%79.6%47.6%
Fair Value Upside
Unlock0.0%5.6%Unlock

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
745.91K2.88%3.45M
Other Institutional Investors
4.96M19.11%22.95M
Public Companies & Retail Investors
20.23M78.01%93.67M
Total
25.93M100.00%120.07M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Cinctive Global Master Fund Ltd.5.36%1,388,8886,431
Cinctive Capital Management LP5.36%1,388,8886,431

People Also Watch

0.934
QTEX
+9.74%
7.5600
ASTC
0.00%
16.960
MRAM
-0.06%
197.73
CBRS
-5.78%
4.2800
MNTS
+3.63%

FAQ

What Is the Neonc Technologies Holdings (NTHI) Stock Price Today?

The Neonc Technologies Holdings stock price today is 4.6800 USD.

What Stock Exchange Does Neonc Technologies Holdings Trade On?

Neonc Technologies Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Neonc Technologies Holdings?

The stock symbol for Neonc Technologies Holdings is "NTHI."

What Is the Neonc Technologies Holdings Market Cap?

As of today, Neonc Technologies Holdings market cap is 113.3500M USD.

What Is Neonc Technologies Holdings's Earnings Per Share (TTM)?

The Neonc Technologies Holdings EPS (TTM) is -2.1361.

When Is the Next Neonc Technologies Holdings Earnings Date?

Neonc Technologies Holdings will release its next earnings report on Nov 13, 2026.

From a Technical Analysis Perspective, Is NTHI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Neonc Technologies Holdings Stock Split?

Neonc Technologies Holdings has split 0 times.

What is the current trading status of Neonc Technologies Holdings (NTHI)?

As of Aug 21, 2026, Neonc Technologies Holdings (NTHI) is trading at a price of 4.6800 USD, with a previous close of 4.5600 USD. The stock has fluctuated within a day range of 4.3900 USD to 4.8899 USD, while its 52-week range spans from 3.0050 USD to 12.9900 USD.

What Is Neonc Technologies Holdings (NTHI) Price Target According to Analysts?

The average 12-month price target for Neonc Technologies Holdings is 16.0000 USD, with a high estimate of 20 USD and a low estimate of 13 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +241.88% Upside potential.

What Is the NTHI Premarket Price?

NTHI's last pre-market stock price is 4.7400 USD. The pre-market share volume is 5,470.0000, and the stock has decreased by 0.1800, or 3.9500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.